{"id":"open-labeladalimumabrescue","safety":{"commonSideEffects":[{"rate":"12-15","effect":"Injection site reactions"},{"rate":"10-15","effect":"Upper respiratory tract infections"},{"rate":"8-12","effect":"Headache"},{"rate":"5-8","effect":"Nausea"},{"rate":"2-4","effect":"Serious infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab is a fully human monoclonal antibody that binds to and neutralizes TNF-alpha, a key pro-inflammatory cytokine. By blocking TNF-alpha signaling, it suppresses the inflammatory cascade and reduces immune cell activation. This mechanism is used as a rescue therapy in patients who have inadequate response to standard treatments.","oneSentence":"Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha to reduce inflammation and immune-mediated disease activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:36.177Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rescue therapy in inflammatory bowel disease (Crohn's disease or ulcerative colitis) with inadequate response to standard therapy"},{"name":"Rescue therapy in rheumatoid arthritis with inadequate response to conventional DMARDs"}]},"trialDetails":[{"nctId":"NCT00870467","phase":"PHASE3","title":"A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":334}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-D2E7","adalimumab","Humira"],"phase":"phase_3","status":"active","brandName":"Open-labelAdalimumabRescue","genericName":"Open-labelAdalimumabRescue","companyName":"Abbott","companyId":"abbott","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha to reduce inflammation and immune-mediated disease activity. Used for Rescue therapy in inflammatory bowel disease (Crohn's disease or ulcerative colitis) with inadequate response to standard therapy, Rescue therapy in rheumatoid arthritis with inadequate response to conventional DMARDs.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}